Faculty Opinions recommendation of A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2010 ◽
Vol 4
◽
pp. CMU.S4960
◽
2008 ◽
Vol 62
(11)
◽
pp. 1675-1683
◽
Keyword(s):